Which of the following is not a steroid?
Glycosphingolipids are composed of which of the following?
Which of the following enzymes is common to the synthesis of cholesterol and ketone bodies?
Bile acid synthesis is autoregulated by which enzyme?
Refsum's disease, characterized by the accumulation of phytanic acid, is due to a defect in which of the following metabolic processes?
In the liver, what are the precursors of ketone bodies?
What alcohol is present in ceramide?
Which organelle is involved in the case of sphingomyelin deficiency?
All of the following are essential fatty acids except?
Which among the following is a cardioprotective fatty acid?
Explanation: **Explanation:** The core concept tested here is the biochemical classification of hormones based on their chemical structure. **Why Relaxin is the correct answer:** Relaxin is **not a steroid**; it is a **peptide hormone** belonging to the insulin-like growth factor family. It consists of two peptide chains (A and B) linked by disulfide bridges. Produced primarily by the corpus luteum and placenta, its main physiological role is to relax the pelvic ligaments and soften the cervix during childbirth. Because it is a protein, it acts via G-protein coupled receptors (GPCRs) on the cell surface, unlike steroids which act on intracellular receptors. **Analysis of incorrect options:** All other options are derivatives of **Cholesterol** and contain the characteristic **cyclopentanoperhydrophenanthrene (CPPP) ring** structure: * **Pregnenolone:** The "mother of all steroids," it is the first steroid formed from cholesterol by the action of the enzyme Desmolase (CYP11A1). * **17α Hydroxyprogesterone:** A key intermediate in the adrenal steroidogenesis pathway, specifically in the synthesis of cortisol and androgens. * **Estrone (E1):** A classic steroid hormone and one of the three major naturally occurring estrogens. **High-Yield Clinical Pearls for NEET-PG:** * **Steroid Nucleus:** All steroids have 17 carbon atoms arranged in four rings (A, B, C, D). * **Carbon Counts:** Remember the "21-19-18" rule: Progestogens/Corticoids have 21 carbons, Androgens have 19, and Estrogens have 18. * **Rate-limiting step:** The conversion of Cholesterol to Pregnenolone in the mitochondria is the rate-limiting step of steroidogenesis. * **Relaxin Clinical Use:** It is a marker of luteal function and plays a role in renal hemodynamics during pregnancy.
Explanation: **Explanation:** Glycosphingolipids are a subtype of glycolipids found predominantly in the outer leaflet of plasma membranes, particularly in nervous tissue. To understand their composition, one must look at their structural hierarchy: 1. **Ceramide:** This is the structural backbone of all sphingolipids. It is formed by the combination of **Sphingosine** (an 18-carbon amino alcohol) and a **Fatty acid** via an amide linkage. 2. **Carbohydrate Component:** In glycosphingolipids, a sugar unit (such as **Glucose** or Galactose) is attached to the primary hydroxyl group of the Ceramide. Therefore, **Option D** is correct because a glycosphingolipid (like Glucosylceramide) contains all three components: a sugar (Glucose), the amino alcohol (Sphingosine), and a long-chain Fatty acid. **Analysis of Options:** * **A, B, and C:** While each of these is a constituent, selecting any single one would be incomplete. A glycosphingolipid is defined by the union of a carbohydrate (A) with a ceramide (B + C). **High-Yield Clinical Pearls for NEET-PG:** * **Neutral Glycosphingolipids:** Cerebrosides (contain a single sugar, usually Galactose in the brain). * **Acidic Glycosphingolipids:** Gangliosides (contain N-acetylneuraminic acid/NANA) and Sulfatides (contain sulfate groups). * **Clinical Correlation:** Deficiencies in the lysosomal enzymes that degrade these lipids lead to **Sphingolipidoses** (e.g., Gaucher’s disease is a deficiency of Glucocerebrosidase, leading to the accumulation of Glucosylceramide). * **Key Fact:** Unlike phospholipids, sphingolipids do **not** contain a glycerol backbone.
Explanation: **Explanation:** The synthesis of both cholesterol and ketone bodies begins with the condensation of acetyl-CoA molecules. The enzyme **HMG-CoA Synthase** is the common link, as it catalyzes the conversion of Acetoacetyl-CoA and Acetyl-CoA into **3-hydroxy-3-methylglutaryl-CoA (HMG-CoA)**. * **In Cholesterol Synthesis:** This occurs in the **cytosol** of almost all nucleated cells (primarily the liver). * **In Ketogenesis:** This occurs in the **mitochondria** of hepatocytes. **Analysis of Options:** * **A. HMG-CoA Reductase:** This is the **rate-limiting enzyme** for cholesterol synthesis only. It converts HMG-CoA to Mevalonate. It plays no role in ketogenesis. * **B. HMG-CoA Lyase:** This enzyme is specific to **ketogenesis**. It breaks down HMG-CoA into Acetoacetate and Acetyl-CoA. It is absent in the cytosolic cholesterol pathway. * **D. Thiokinase (Acetoacetyl-CoA Synthetase):** While involved in activating fatty acids or ketone bodies, it is not the shared enzymatic step for the synthesis of these two specific pathways. **NEET-PG High-Yield Pearls:** 1. **Compartmentalization:** Remember that HMG-CoA Synthase has two isoforms: **Cytosolic** (Cholesterol) and **Mitochondrial** (Ketones). 2. **Rate-Limiting Steps:** The rate-limiting enzyme for Cholesterol synthesis is **HMG-CoA Reductase**, whereas for Ketogenesis, it is **HMG-CoA Synthase** (mitochondrial). 3. **Statin Target:** Statins (e.g., Atorvastatin) competitively inhibit HMG-CoA Reductase, not the synthase. 4. **Ketolysis:** The liver cannot utilize ketone bodies because it lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA-transferase).
Explanation: **Explanation:** **1. Why 7-Alpha Hydroxylase is Correct:** Bile acid synthesis occurs in the liver, where cholesterol is converted into primary bile acids (Cholic acid and Chenodeoxycholic acid). **7-Alpha hydroxylase** is the **rate-limiting and committed step** in this pathway. It is subject to **feedback inhibition (autoregulation)**: high levels of bile acids returning to the liver via enterohepatic circulation downregulate the expression of the CYP7A1 gene (which encodes this enzyme), thereby slowing further synthesis. **2. Analysis of Incorrect Options:** * **B. 11-alpha hydroxylase:** This enzyme is not involved in bile acid synthesis. It is primarily associated with steroid hormone metabolism in the adrenal cortex (though 11-beta hydroxylase is the more clinically significant enzyme in that pathway). * **C. Acetoacetyl-CoA thiolase:** This enzyme is involved in **ketogenesis** and the early steps of cholesterol synthesis (converting Acetyl-CoA to Acetoacetyl-CoA), but it does not regulate bile acid production. * **D. Desmosterol reductase:** This is the final enzyme in the **Bloch pathway** of cholesterol biosynthesis, converting desmosterol to cholesterol. It is not the regulatory point for bile acids. **3. Clinical Pearls & High-Yield Facts:** * **Cofactors:** 7-Alpha hydroxylase is a cytochrome P450 enzyme and requires **Vitamin C**, NADPH, and Molecular Oxygen. Vitamin C deficiency can lead to cholesterol accumulation and gallstone formation. * **Regulation:** Synthesis is stimulated by **Cholesterol** (substrate induction) and inhibited by **Bile salts** (feedback inhibition). * **Drug Link:** **Cholestyramine** (a bile acid sequestrant) prevents bile acid reabsorption, relieving the feedback inhibition on 7-alpha hydroxylase, which increases the conversion of cholesterol into bile acids, thereby lowering serum LDL levels.
Explanation: **Explanation:** **Refsum’s Disease** is a rare autosomal recessive peroxisomal disorder caused by a deficiency of the enzyme **Phytanoyl-CoA hydroxylase**. This enzyme is essential for **Alpha-oxidation**, the metabolic pathway required to break down branched-chain fatty acids like **phytanic acid**. Phytanic acid is derived from chlorophyll in the diet (dairy and meat). Unlike most fatty acids, it has a methyl group at the beta-carbon position, which sterically hinders Beta-oxidation. To bypass this, alpha-oxidation removes one carbon atom from the carboxyl end, shifting the methyl group to the alpha-position and allowing subsequent Beta-oxidation to proceed. In Refsum’s disease, this initial step fails, leading to the toxic accumulation of phytanic acid in tissues, particularly the brain and skin. **Analysis of Incorrect Options:** * **A & C: Carnitine palmitoyl transferase-I (CPT-I) & Beta-oxidation:** Beta-oxidation is the primary pathway for straight-chain fatty acids in mitochondria. CPT-I is the rate-limiting enzyme for transporting these long-chain fatty acids into the mitochondria. Neither is involved in the initial processing of branched-chain phytanic acid. * **B: HMG-CoA lyase deficiency:** This enzyme is involved in ketogenesis and the catabolism of the amino acid leucine. Deficiency leads to metabolic acidosis and hypoglycemia, not phytanic acid accumulation. **NEET-PG High-Yield Pearls:** * **Clinical Triad of Refsum’s:** Retinitis pigmentosa, peripheral neuropathy, and cerebellar ataxia (often with ichthyosis). * **Treatment:** Strict dietary restriction of chlorophyll-containing foods (green leafy vegetables, ruminant fats). * **Zellweger Syndrome:** Contrast this with Refsum’s; Zellweger is a total failure of peroxisome biogenesis affecting multiple pathways, including Very Long Chain Fatty Acid (VLCFA) oxidation.
Explanation: **Explanation:** Ketogenesis occurs primarily in the mitochondrial matrix of hepatocytes. The correct answer is **Free Fatty Acids (FFAs)** because they serve as the primary substrate for this pathway. 1. **Why Free Fatty Acids are correct:** During fasting, starvation, or uncontrolled diabetes, low insulin and high glucagon levels trigger **lipolysis** in adipose tissue. This releases FFAs into the blood, which are taken up by the liver. Inside the mitochondria, FFAs undergo **beta-oxidation** to produce **Acetyl-CoA**. When Acetyl-CoA levels exceed the capacity of the TCA cycle, it is diverted into the HMG-CoA lyase pathway to form ketone bodies (Acetoacetate, 3-Hydroxybutyrate, and Acetone). 2. **Why other options are incorrect:** * **Triacylglycerols (TAGs):** While TAGs are the storage form of lipids, they must first be hydrolyzed into FFAs and glycerol before they can enter the ketogenic pathway. * **Cholesterol & Cholesteryl esters:** These are structural lipids or precursors for steroid hormones and bile acids. They cannot be broken down into Acetyl-CoA for energy or ketone body synthesis in humans. **High-Yield Clinical Pearls for NEET-PG:** * **Rate-limiting enzyme:** HMG-CoA Synthase (Mitochondrial isoform). * **Site of synthesis:** Liver (Mitochondria). * **Site of utilization:** Extrahepatic tissues (Brain, Heart, Skeletal muscle). * **Why the liver cannot use ketones:** It lacks the enzyme **Thiophorase** (Succinyl-CoA:3-ketoacid CoA transferase). * **Ketone bodies in urine:** Detected by **Rothera’s Test** (specifically detects Acetoacetate and Acetone, but not Beta-hydroxybutyrate).
Explanation: **Explanation:** The core structure of all sphingolipids is **Ceramide**. A ceramide is formed when a long-chain fatty acid is attached to the amino group of **Sphingosine** (an 18-carbon amino alcohol) via an **amide linkage**. 1. **Why Sphingosine is correct:** Sphingosine serves as the structural backbone for complex lipids found in cell membranes, particularly in the myelin sheath. When a fatty acid is added to sphingosine, it forms Ceramide. If a polar head group is further added to ceramide (like phosphorylcholine), it becomes Sphingomyelin. 2. **Why Glycerol is incorrect:** Glycerol is the alcohol backbone for **Glycerophospholipids** (e.g., Lecithin, Cephalin) and Triacylglycerols (TAGs). In these molecules, fatty acids are attached via ester linkages, not amide linkages. 3. **Why Ethanol and Methanol are incorrect:** These are simple monohydric alcohols. While ethanolamine (derived from ethanol) can be a head group in phospholipids, neither serves as the structural backbone for complex membrane lipids. **High-Yield Clinical Pearls for NEET-PG:** * **Ceramide + Phosphorylcholine = Sphingomyelin** (The only phospholipid that does *not* contain glycerol). * **Ceramide + Sugar = Glycosphingolipids** (e.g., Cerebrosides, Gangliosides). * **Farber’s Disease:** A rare lipid storage disorder caused by a deficiency of the enzyme **ceramidase**, leading to the accumulation of ceramide in tissues (presents with painful joint swelling and hoarseness). * **Sphingomyelinase deficiency** leads to **Niemann-Pick Disease**, characterized by "foamy cells" and hepatosplenomegaly.
Explanation: ### Explanation **1. Why Lysosome is Correct:** The deficiency of enzymes responsible for breaking down sphingomyelin (specifically **Acid Sphingomyelinase**) leads to **Niemann-Pick Disease**. Lysosomes are the primary site for the degradation of complex macromolecules, including sphingolipids. When a specific lysosomal hydrolase is deficient, the substrate (sphingomyelin) cannot be degraded and subsequently accumulates within the lysosome. This categorizes the condition as a **Lysosomal Storage Disorder (LSD)**. **2. Why Other Options are Incorrect:** * **Nucleus:** This organelle houses genetic material (DNA) and is responsible for transcription. While the genetic mutation originates here, the metabolic pathology occurs in the cytoplasm. * **Mitochondria:** These are the "powerhouses" of the cell, primarily involved in ATP production via oxidative phosphorylation and fatty acid $\beta$-oxidation, not the degradation of complex structural sphingolipids. * **Cell Membrane:** While sphingomyelin is a major structural component of the plasma membrane and myelin sheaths, the *deficiency* or metabolic defect manifests in the degradative machinery (lysosomes), not the membrane itself. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Niemann-Pick Disease (Type A & B):** Caused by Acid Sphingomyelinase deficiency. * **Histology:** Look for **"Foam Cells"** (lipid-laden macrophages with a vacuolated appearance) in the bone marrow or spleen. * **Clinical Triad:** Hepatosplenomegaly, progressive neurodegeneration, and a **Cherry-red spot** on the macula (also seen in Tay-Sachs, but Tay-Sachs lacks hepatosplenomegaly). * **Inheritance:** All sphingolipidoses are **Autosomal Recessive**, except for Fabry disease (X-linked Recessive).
Explanation: **Explanation:** The correct answer is **Lysergic acid**. **1. Why Lysergic acid is the correct answer:** Essential Fatty Acids (EFAs) are polyunsaturated fatty acids (PUFAs) that the human body cannot synthesize de novo because humans lack the enzymes (**$\Delta^{12}$ and $\Delta^{15}$ desaturases**) necessary to introduce double bonds beyond the $\Delta^9$ position. **Lysergic acid** is not a fatty acid at all; it is a precursor for ergoline alkaloids (like LSD) and is chemically unrelated to lipid metabolism. **2. Analysis of incorrect options:** * **Linoleic acid ($\omega$-6):** A primary essential fatty acid (18:2; $\Delta^{9,12}$). It is the precursor for arachidonic acid. * **Linolenic acid ($\omega$-3):** Specifically $\alpha$-linolenic acid (18:3; $\Delta^{9,12,15}$), it is a primary essential fatty acid crucial for brain development and cardiovascular health. * **Arachidonic acid ($\omega$-6):** It is considered a **conditionally essential** fatty acid. While the body can synthesize it from linoleic acid, it becomes essential if linoleic acid is deficient in the diet. In many competitive exams, it is classified under the broad category of essential fatty acids. **High-Yield Clinical Pearls for NEET-PG:** * **True Essential Fatty Acids:** Only Linoleic and $\alpha$-Linolenic acid are strictly essential. * **Deficiency Manifestations:** EFA deficiency leads to **Phrynoderma** (follicular hyperkeratosis/toad skin), poor wound healing, and hair loss. * **Omega Nomenclature:** $\omega$-3 (Linolenic) and $\omega$-6 (Linoleic/Arachidonic) are classified based on the position of the first double bond from the methyl (omega) end. * **Prostaglandin Precursor:** Arachidonic acid is the immediate precursor for the synthesis of eicosanoids (prostaglandins, thromboxanes, and leukotrienes).
Explanation: **Explanation:** **1. Why Omega-3 fatty acid is correct:** Omega-3 fatty acids (e.g., Alpha-linolenic acid, EPA, and DHA) are Polyunsaturated Fatty Acids (PUFAs) renowned for their **cardioprotective** properties. They reduce cardiovascular risk through multiple mechanisms: * **Hypolipidemic effect:** They significantly lower plasma triglyceride levels by inhibiting VLDL synthesis. * **Anti-thrombotic effect:** They shift the balance of eicosanoids toward less inflammatory and less pro-aggregatory forms (increasing PGI3 and TXA3), thereby reducing platelet aggregation. * **Anti-inflammatory & Anti-arrhythmic:** They stabilize the electrical activity of cardiac myocytes and reduce arterial inflammation. **2. Why the other options are incorrect:** * **Palmitic acid (16C) & Stearic acid (18C):** These are **Saturated Fatty Acids (SFAs)**. High intake of SFAs (especially Palmitic acid) is associated with increased LDL-cholesterol levels and a higher risk of atherosclerosis. While Stearic acid is considered relatively neutral compared to Palmitic acid, it is not classified as "cardioprotective." * **Oleic acid (18:1; ω-9):** This is a Monounsaturated Fatty Acid (MUFA) found in olive oil. While it is "heart-healthy" as a replacement for saturated fats, Omega-3 fatty acids are the gold standard for active cardioprotection in medical literature due to their specific anti-inflammatory and triglyceride-lowering profiles. **Clinical Pearls for NEET-PG:** * **Essential Fatty Acids:** Linoleic acid (ω-6) and Linolenic acid (ω-3) are essential because humans lack **Δ12 and Δ15 desaturases**. * **P/S Ratio:** A high Polyunsaturated to Saturated fat ratio in the diet is recommended to prevent coronary artery disease. * **Fish Oil:** Rich source of EPA (Eicosapentaenoic acid) and DHA (Docosahexaenoic acid), which are potent ω-3 fatty acids.
Lipid Classification and Chemistry
Practice Questions
Fatty Acid Oxidation
Practice Questions
Ketone Body Metabolism
Practice Questions
Fatty Acid Synthesis
Practice Questions
Metabolism of Triacylglycerols
Practice Questions
Phospholipid Metabolism
Practice Questions
Cholesterol Metabolism and Biosynthesis
Practice Questions
Bile Acids and Bile Salts
Practice Questions
Lipoprotein Metabolism and Transport
Practice Questions
Dyslipidemias and Atherosclerosis
Practice Questions
Prostaglandins and Eicosanoids
Practice Questions
Fatty Liver and Lipotropic Factors
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free